Acorda Therapeutics, Inc. Nasdaq

ACOR

US00484M7002

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 03:59:57 2024-04-25 pm EDT			5-day change	1st Jan Change
0.75 ^USD	+36.36%		+121.24%	-95.03%

Apr. 15	Acorda Therapeutics Delisted from Nasdaq, Now Trading on OTC Pink Market	MT
2023	Transcript : Acorda Therapeutics, Inc., Q2 2023 Earnings Call, Aug 08, 2023

Acorda Therapeutics, Inc. Provides Earnings Guidance for the Fiscal 2021

August 05, 2021 at 04:01 pm EDT

Acorda Therapeutics, Inc. provided earnings guidance for the fiscal 2021. For the full-year 2021, Acorda continues to expect AMPYRA net revenue to be $75 - $85 million.

Latest news about Acorda Therapeutics, Inc.

Acorda Therapeutics Delisted from Nasdaq, Now Trading on OTC Pink Market	Apr. 15	MT
Transcript : Acorda Therapeutics, Inc., Q2 2023 Earnings Call, Aug 08, 2023	23-08-08

Chart Acorda Therapeutics, Inc.

Duration

Period

More charts

Acorda Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. The Company markets Inbrija (levodopa inhalation powder), which is approved in the United States for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinsonâs disease treated with carbidopa/levodopa. Inbrija is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor, such as phenelzine or tranylcypromine within the last two weeks. Inbrija utilizes its ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. ARCUS is a dry-powder pulmonary drug delivery technology. It also markets the branded AMPYRA (dalfampridine) extended-release tablets, 10 mg, to improve walking in adults with multiple sclerosis. Ampyra is marketed as Fampyra outside the United States by Biogen International GmbH.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.26%	103B
REGENERON PHARMACEUTICALS, INC.	+1.41%	95.71B
ARGENX SE	+0.79%	22.02B
BIONTECH SE	-17.84%	20.9B
GENMAB A/S	-11.11%	17.85B
WUXI APPTEC CO., LTD.	-42.83%	16.21B
BEIGENE, LTD.	-17.63%	15.52B
NEUROCRINE BIOSCIENCES, INC.	+4.55%	13.86B
SAREPTA THERAPEUTICS, INC.	+32.11%	12.04B